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Incarcerated persons are a population long
recognized as being at higher risk for tubercu-
losis (TB) than the general population.8 Of the
15,989 reported cases of active TB in the
U.S. in 2001, 3.3% were in residents of
correctional facilities at the time of diagnosis.6
At the same time, 0.7% of the total U.S.
population was incar-
cerated in a prison or
jail.17 Correctional    facil-
ities have been recog-
nized as reservoirs
for the spread of
Mycobacterium tubercu-
losis infection and TB
disease among inmates
and communities.15 The
prevalence of HIV infec-
tion among inmates is an
additional factor leading to higher rates of TB
disease and TB infection in prison and jail set-
tings. Control of TB in these high-risk environ-
ments is important for the health of inmates,
their contacts (once released), and for the
continued decrease in the national TB case
rate.
Mycobacterium tuberculosis
TB is a disease caused by the organism M.
tuberculosis. In most cases, TB affects the
lungs, although the disease can occur in any
organ system of the body. Symptoms of TB
include fever, weight loss, night sweats, and
fatigue. For those with the pulmonary form of
the disease, there is usually a productive
cough and abnormal chest radiograph. In
advanced forms of pulmonary TB, hemoptysis
may be present. 
M. tuberculosisis transmitted by airborne par-
ticles called droplet nuclei that are generated
by coughing when a person has pulmonary
TB. The particles are an estimated one to five
microns in size, and can remain suspended in
an enclosed room for periods of 30 minutes or
longer. Although not all exposed persons
become infected, infection occurs when a sus-
ceptible person inhales droplet nuclei contain-
ing M. tuberculosis,which then reach the alve-
oli of the lungs. The probability that a person
who is exposed to M. tuberculosiswill become
infected depends mainly on the concentration
of infectious droplet nuclei in the air, the per-
son's underlying immune status, nutritional
state, and the duration of exposure. The con-
centration of droplet nuclei in the air is deter-
mined by characteristics of the contagious
patient and environmental factors. These
characteristics include the
presence of cough,
whether the disease is in
the lungs, airways, or lar-
ynx, whether acid fast
bacilli (AFB) are present on
smears of sputum speci-
mens, and whether there
are pulmonary cavities on
the chest radiograph.
Environmental factors
include exposure in small,
enclosed spaces and poor ventilation.9
Latent TB infection (LTBI)
A small proportion of persons who are infected
with TB will develop disease within weeks to
months after exposure. For most infected per-
sons, within two to 12 weeks, the immune sys-
tem limits multiplication and spread of the
organism. When this occurs, some of the
organisms remain dormant in the body but are
viable for many years. This condition is
referred to as latent TB infection (LTBI).
Persons with LTBI have no symptoms of TB
isease and are not infectious. A proportion of
persons with LTBI will develop TB disease dur-
ing their lifetime. The risk is greatest during
the first several years after infection.
Immunocompromised persons with LTBI have
a high risk for progression to TB disease; HIV
infection is the strongest known risk factor for
this progression.10 Treatment for LTBI greatly
reduces the likelihood that TB disease will
develop.
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Infectious Diseases in Corrections
Taking Control of Tuberculosis in Corrections
By Renee Ridzon, M.D.*
Continued on page 2
Of the 15,989 reported
cases of active TB in 
the U.S. in 2001, 
3.3% were in residents 
of correctional facilities 
at the time of diagnosis.
The tuberculin skin test (TST) can be use-
ful in the diagnosis of LTBI and TB dis-
ease. In most cases of LTBI or disease,
the TST is positive. However a negative
test by itself should never be used to rule
out infection or disease if there is a high
clinical suspicion for either of these condi-
tions or there are symptoms consistent
with TB disease, especially in HIV-infect-
ed patients - where TST can be negative
despite active TB disease.
Most cases of TB are caused by organ-
isms susceptible to all antituberculosis
medications, and disease cure rates are
high when there are at least six months of
effective treatment and good adherence.
If rifampin is not included in the regimen
then the length of treatment is prolonged.
Cases caused by organisms with resis-
tance to antituberculosis medications may
require longer treatment and therapy that
includes less effective second-line agents.
Multidrug resistant (MDR) TB, defined as
TB caused by organisms demonstrating
resistance to at least isoniazid and
rifampin (the two most potent antitubercu-
losis medications), is the most difficult
form of TB to treat and requires prolonged
therapy, the use of less effective, more
toxic second-line antituberculosis drugs,
and an occasional need for surgery. MDR
TB has a high rate of mortality and mor-
bidity, although this has improved in
recent years.2
Epidemiology in jails and
prisons
In both jails and prisons, TB rates among
inmates far exceed those of the general
U.S. population. In one study from 1995 to
1997 in the Memphis County, Tenn., Jail,
the calculated incidence of TB cases was
274 per 100,000, over 35 times the
national rate and 20 times that of
Memphis County for the corresponding
time period.15 In prisons in New York State
during 1993, the reported TB case rate
was 139.3 cases per 100,000; for New
Jersey prisons the rate reported for 1994
was 91.2 cases per 100,000; and for
California prisons in 1991 there were 184
cases per 100,000. In all three states, the
TB rates among inmates were six to 10
times that of the state's general popula-
tion.8
Some facilities have seen a marked
decline in the number of active TB dis-
ease due to diligent TB control programs
with mandated screening and directly
observed treatment of LTBI. In the New
York State DOC the rate of TB disease
was 225/100,000 in 1991. By 2001, the
rate for new cases of active TB disease
decreased to 11/100,000. That rate was
comparable to the rate in Manhattan even
though nearly one-quarter of all incoming
inmates were infected with TB. 
At California Medical Facility in the
California Department of Corrections, sim-
ilar control measures effectively aborted
an outbreak of TB in a dedicated HIV
housing unit. After 22 cases of TB disease
occurred over a five month period in 1995
(a case rate of 21,100/100,000 person
years), there have been no new cases of
TB disease in the past seven years.18
The role of HIV 
co-infection
There are a number of factors that con-
tribute to the increased incidence of TB
infection and disease among incarcerated
populations. These risk factors include
HIV infection, substance use and depen-
dence, poor access to health care, and
overcrowding and poor ventilation within
correctional facilities.8 The strongest of
these risk factors is HIV infection. In 1997
HIV infection was present in an estimated
2.1% of persons incarcerated in state and
federal prisons, and the rate of AIDS
among prisoners was five times than that
of the general population. Concurrent with
the increasing number of prisoners in the
country, there has been an increase in the
number of inmates with HIV infection.
From 1991 to 2000 the number of HIV-
infected prisoners in state and federal
facilities increased from 17,551 to
25,088.17 The rising number of prisoners
within the country has led to overcrowding
within many correctional facilities, increas-
ing the risk of transmission of M. tubercu-
losis.
Transmission of 
M. tuberculosis within 
correctional facilities
There have been several reports of out-
breaks of TB within U.S. prisons and jails.
11,12,13,14,15,18,19In most of these outbreaks
transmission of a single strain of M. tuber-
culosiswas verified by epidemiology and
strain typing. Some of these outbreaks
involved multidrug resistant strains of M.
tuberculosis. In several cases there was
transmission to correctional facility staff
and members of the communities to which
inmates were released. In the investiga-
tion of TB cases in Memphis County, 43%
of all TB cases reported in 1995 through
1997 were in persons who had previous
contact with the jail. This suggests that the
jail may have played an important role in
contributing to the transmission of M.
tuberculosisin the community as well as
provided a potential location for preven-
tion efforts.15
HIV infection was a major factor in most
reported correctional outbreaks. Reasons
for this include the increased rate of reac-
tivation of LTBI in those infected with HIV,
elayed diagnosis in HIV-infected source
cases due to atypical presentation of TB
disease, and the rapid development of
disease in HIV-infected persons who were
ewly infected with M. tuberculosis. In one
outbreak that occurred in a housing unit
for HIV-infected inmates, extensive trans-
mission was documented.3 In this out-
break, there were 30 secondary cases of
TB disease and documentation of new
infection in approximately 70% of the 115
inmates who shared the same side of the
dormitory with the source patient. In this
outbreak, as in others involving HIV-
infected inmates, low CD4 count was a
risk for TB disease. 
In a number of former Soviet Union coun-
tries, there is a serious problem of trans-
mission of M. tuberculosiswithin prisons.
Epidemic TB among prisoners, spread of
disease from the prisons to the communi-
ty, and high rates of MDR TB has been
documented in many prisons in Russia.
Rates of TB in these prisons are among
the highest in the world. In 1997 in Tomsk
Oblast of Siberia, TB notification rates for
the incarcerated population were 4,000
cases per 100,000. The mortality rate
from TB among prisoners at that time was
485 per 100,000.16 MDR TB rates
throughout the former Soviet Union are
2
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Table 1. Two-step testing
In some persons with LTBI, reaction to tuberculin may wane over years. When these
persons are skin tested years after infection, they may have a negative reaction.
However, the skin test may stimulate (or "boost") their ability to react to tuberculin,
resulting in a positive reaction to a subsequent test. With serial testing, the boosted
reaction may be misinterpreted as a newly acquired infection. Two-step testing is used
to establish a reliable baseline TST status and reduce the likelihood that a boosted reac-
tion will be misinterpreted as a recent infection. Two-step testing is performed by admin-
istering a skin test; if that test result is negative, then a second-step test should be given
one to three weeks later. A positive reaction to the second-step test of the two-step test
probably represents a boosted reaction. The boosted reaction should not be considered
a TST conversion. Two-step testing should be used only for baseline screening and
never should be used in a contact investigation.
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Dear Correctional Colleagues:
In my infectious diseases referral clinic in a state prison in California, at least once a week 
encounter a patient who has a chronic medical condition for which no treatment was pursued
prior to incarceration. Whether it is mental illness, HIV, HCV, LTBI, or a myriad of other treat-
able and/or curable conditions, the reality is that this nation's jails and prisons have become
the primary source of medical services for a significant percentage of our fellow citizens. Work
by our colleague Rick Altice has demonstrated that for many inmates with HIV infection, the
first offer of testing and/or treatment came during incarceration. David Thomas, Dianne
Rechtine, and colleagues in Florida were able to show that directly observed therapy in a
prison setting can yield remarkable results in the treatment of HIV disease. How can these
lessons be applied to this country's strategic plan for the elimination of tuberculosis?  
As noted in the recent report to congress entitled "The Health Status of Soon-To-Be-Released
Inmates," we know that inmates are disproportionately burdened by tuberculosis infection a d
disease. It is estimated that over 500,000 individuals with LTBI are released from jail or prison
every year, and that the rate of active tuberculosis in inmates is at least five times that found
in persons in the free community. Clearly, many inmates are also struggling with mental illness,
alcoholism, substance abuse, poverty, and other problems that impact upon their willingness
and ability to faithfully adhere to the long treatment course required for LTBI and TB disease.
Once again, we in correctional/public health are called upon to turn this challenge into an
opportunity: to use the period of incarceration of our patients as a time to diagnose, educate,
and treat those of our patients who are infected with tuberculosis. By doing so, we not only
make an impact on the health of our patients, but also contribute to the nation's public health
efforts to eliminate TB.
This month, Dr. Renee Ridzon provides a review of the current status of tuberculosis in cor-
rections, and HEPP Report editors provide a summary of a CDC-sponsored conference held
January 25-26 in San Antonio on the management of HCV in corrections.  This month's HIV
101 is a useful table to guide the treatment of LTBI.
After reading this issue, you should be familiar with the diagnosis and treatment of MTB in the
incarcerated, and have a better understanding of current issues involved in the management
of HCV in the correctional setting. 
Joseph Bick, M.D.
Co-Chief Editor
Letter from the Editor
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also among the highest in the world and in
some prisons, up to 23% of isolates from
newly-diagnosed cases of TB are MDR.
For retreatment cases this proportion is
even higher. With the combination of
increasing rates of incarceration, especially
due to sentences related to injection drug
use, and increasing rates of HIV infection
among these injection drug users, this
problem could become even more serious. 
Screening for TB Disease
Correctional facilities are settings where
intensive measures for TB screening, con-
trol and prevention are needed. Screening
activities should include inmates as well as
employees. Screening should consist of
assessing inmates for TB disease and LTBI
or histories of either, with a high priority
placed upon the prompt diagnosis and iso-
lation of inmates with suspected infectious
pulmonary disease. This is important since
transmission of M. tuberculosisin correc-
tional facilities can be extensive from per-
sons with undiagnosed, infectious TB. 
All newly admitted inmates should be
screened for symptoms of TB disease at
the time of arrival. If symptoms suggestive
of TB disease are present, further diagnos-
tic work-ups should be performed, includ-
ing a chest radiograph and collection of
sputum specimens. If there is any suspi-
cion that the inmate may have pulmonary
disease, he or she should be placed in air-
borne infection isolation as soon as possi-
ble to prevent transmission of infection to
others in the correctional facility and should
remain isolated until there is a determina-
tion that the inmate does not have poten-
tially infectious TB. The airborne isolation
of the suspected infectious inmate should
occur before the initiation of the work-up. If
the suspicion is high enough to warrant col-
lection of sputa specimens, especially if
HIV co-infection is present, then the inmate
should be in isolation.
In addition to screening for symptoms of TB
disease upon admission, the index of sus-
picion for TB should be high for any inmate
who presents with cough. In many out-
breaks, extensive transmission from undi-
agnosed cases occurred because TB was
not considered as a diagnosis in source
cases until late in the course of illness. It is
especially important to consider TB early in
settings with HIV-infected inmates because
of their increased risk of developing dis-
ease once infected. In persons with HIV
infection, TB may have an atypical clinical
and radiographic presentation. There has
been extensive transmission documented
from HIV-infected source patients who had
minimal chest radiograph abnormalities.
Screening for LTBI
Screening for LTBI is important since treat-
ment is an effective prevention tool. This is
especially true for incarcerated persons
since the risk of reactivation disease is
higher than that of the general population
due to immune deficiency, drug use, or
recent infection. The preferred method of
screening for LTBI is the Mantoux method
for the TST. Multiple puncture tests are not
recommended. Bacille Calmette-Guèrin
(BCG) vaccination, pregnancy, or undocu-
mented history of a prior positive skin test
are not contraindications to tuberculin skin
testing. Because the skin test must be read
(always by a trained health care worker) 48
to 72 hours after placement, screening in
short-term facilities may be difficult due to
high turnover of inmates. In general, 10
mm of induration is defined as a positive
skin test, although in special circumstances
such as a contact investigation or HIV
infection, 5 mm is used to define a positive
test.3 In contact investigations and in per-
sons in whom the suspicion of infection is
high, treatment of LTBI is sometimes given
even when the skin test is negative (espe-
cially in the case of HIV infection).
All inmates and employees with initial neg-
ative skin tests should have periodic skin
testing performed. In most cases, this is
performed annually. In all populations
where periodic screening occurs, two-step
testing (see Table 1) should be initially per-
formed to establish a reliable baseline.8
Periodic screening is an important part of
TB control since an unexpected number of
positive skin tests or conversions may sig-
nal transmission from an undiagnosed
case of infectious TB and indicate that an
investigation should be initiated.
Treating TB Disease and
LTBI
TB disease and LTBI should ideally be
treated by someone experienced in the
management of TB, or in consultation with
someone with such experience. Treatment
guidelines have been published (see
below), and new treatment guidelines are
expected soon.1,3,4,5,7,10 Treatment for all
inmates with TB disease and ideally for
LTBI should be directly observed to ensure
adherence with and completion of treat-
ment. All cases of suspected TB disease
should be promptly reported to the local TB
control program and a contact investigation
should be initiated if indicated. 
Isoniazid has been most commonly used
for treatment of LTBI. In 2000, the CDC
issued recommendations for use of a short
course regimen of two months of rifampin
and pyrazinamide for treatment of LTBI.
Since that time, there have been reports of
44 cases of severe liver injury (including 10
fatalities) associated with this regimen. As
a result, isoniazid for nine months is the
preferred regimen for treatment of LTBI and
should be used whenever possible (an
alternative is the use of four months of
rifampin. See HIV 101 for use with pro-
tease inhibitors and non-nucleoside
reverse transcriptase inhibitors.) The use of
rifampin and pyrazinamide should be
avoided when possible. If rifampin and
pyrazinamide are used, there should be
extremely close monitoring for symptoms
or abnormalities in levels of serum amino-
transferases and bilirubin. Rifampin and
pyrazinamide should never be used in per-
sons who have experienced liver injury with
prior use of isoniazid, or who are preg-
nant.5,6
Conclusion
Because correctional facilities house popu-
lations at higher risk for TB, close attention
to TB control is very important. Screening
for infection and disease can lead to
prompt diagnosis of infection or disease,
prevention of transmission, and completion
of treatment of either infection or disease.
Attempts should be made to coordinate all
TB control activities with the local health
department. Doing so can enhance overall
TB prevention and care, for example by
ensuring treatment completion for inmates
upon release to the community. Good TB
control in correctional facilities will lead to
decreased transmission of M. tuberculosis
and prevention of cases among inmates as
well as in the communities from which the
inmates return to upon release. 
For more information and publications
regarding TB treatment prevention and
control, visit the CDC's Division of
Tuberculosis Elimination website at
http://www.cdc.gov/nchstp/tb/.
*Disclosures: Nothing to disclose.
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Treatment  of LTBI 
At risk: PPD+ (>5 mm induration) without prior treatment of LTBI
Preferred Regimen
INH 5mg/kg per day, max dose of
300mg/day + pyridoxine 50 mg/day,
x 9 months
INH 15 mg/kg up to a dose of 900+
pyridoxine 100 mg 2x/wk, x 9
months
Alternative Regimen**
RIF 10 mg/kg up to 600 mg per day
mg/day + PZA 15-20 mg/kg/day x 2
months (see CAUTION below)
RIF 10 mg/kg up to 600 mg/day x 4
months
**Patients receiving PI or NNRTI
should not receive RIF.  With some
antiretrovirals, rifabutin can be sub-
stituted for RIF with an antiretroviral
dose adjustment. Consult an expert.
*CAUTION: Cases of severe liver injury, some fatal, have been associated with the use of RIF/PZA for the treatment of
LTBI.  The RIF/PZA regimen is contraindicated in those with alcoholism and those with liver injury during prior use of
INH. Avoid two-month regimens except perhaps in high-risk cases with impending parole or release who are unlikely to
continue therapy after release. Full information on recommendations concerning RIF/PZA are available in the August
2001 MMWR 50 (34): 733-735 or at http://www.cdc.gov/mmwr/PDF/wk/mm5034.pdf
Monitoring:Baseline bilirubin, AST & ALT, add CBC if treated w/RIF or RFB. Repeat tests if baseline tests are abnor-
mal or if there are symptoms of hepatitis. Recipients of INH or RIF alone: symptom review monthly.  For those receiving
PZA plus RIF or RFB, more careful monitoring to include LFTs at two, four and six weeks.
EMB = ethambutol, INH = isoniazid, PZA = pyrazinamide, RFB = rifabutin, RIF = rifampin, SM = streptomycin
Special Cases
INH-resistant strain:
RIF 10 mg/kg up to 600 mg/day x 4
months.  RIF 10 mg/kg up to 600
mg per day + PZA 15-20 mg/kg/day
x 2 months  (see CAUTION below) 
INH- and RIF-resistant strain:
Treat in consultation with an expert
in MDR TB.
Pregnancy:
Use INH regimen.
Adapted from Bartlett JG, Gallant JE. Medical Management of HIV Infection 2001-2002 Edition.
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Conference Report: Management of Hepatitis C in Corrections
A diverse group of correctional health care professionals from pris-
ons and jails, federal representatives, academics, hepatitis C
experts, lawyers, and public health advocates gathered recently for
a key meeting on managing hepatitis C in prisons ("Management of
Hepatitis C in Prisons 2003," January 25-26, 2003, San Antonio,
Texas). The official goals of the conference were to describe the
prevalence of hepatitis C virus (HCV) in prisons and understand how
two recently released federal documents on the diagnosis and treat-
ment of HCV pertain to prison populations.(1,2) 
However, as Anne Spaulding, MD, of the Centers for Disease
Control (CDC) Division of Viral Hepatitis made clear in her opening
statement, the goal of many of the professionals present at the
meeting was to establish a new consensus on the treatment of HCV
in correctional settings. She described plans to publish the proceed-
ings in a monograph that would help establish national guidelines for
the management of HCV in correctional settings.
While it was difficult to reach a consensus, different approaches
were shared (and debated) with the goal of better understanding the
epidemic facing the nation's prisons and creating effective approach-
es to managing it. The conference focused on the management of
HCV in prisons; adequately discussing management of HCV in jails
was thought too large a scope for the meeting. 
Background
The first session was devoted to reviews of scientific data on the
pathogenesis, and treatment of HCV. Stanley Lemon, MD, of the
University of Texas Medical Branch (UTMB) summarized virological
aspects and contrasted the prognosis and management of HIV and
HCV (Figure 1). 
Prevalence
Ted Hammett, PhD, (Abt Associates) presented data from studies
supported by the National Commission on Correctional Health Care
(NCCHC), the CDC, the National Institute of Justice (NIJ), and the
Bureau of Justice Statistics (BJS) on the prevalence of HCV in cor-
rections. He presented revised estimates based on these studies
suggesting that 17% to 25% of inmates in the nation's correctional
facilities have chronic HCV infection. Based on these data, Dr.
Hammett estimated that 1.3 to 1.9 million individuals passing
through correctional facilities every year have HCV infection, repre-
senting 29% to 42% of the total number of HCV-infected persons in
the United States (estimated at 4.5 million). This means that the cor-
rectional population provides a remarkable opportunity to diagnose,
educate patients, and treat HCV in the United States. He also dis-
cussed the "ripple effect" of this blood-borne infection on public
health following the return of HCV-infected inmates to their home
community.
Testing
Two approaches to testing were discussed: universal and targeted.
As discussed by Dean Reiger, MD, of the Indiana Department of
Corrections, HCV testing became universal in Indiana prisons in July
2002 despite objections relating to fiscal concerns (there was no
additional funding allotted with the legislation). Indiana now performs
three separate tests for each offender: HIV, HCV, and syphilis. Initial
results show that 13% of inmates in Indiana prisons are HCV-posi-
tive.
David Burnett, MD, of the Wisconsin Department of Corrections dis-
cussed targeted HCV testing now practiced in Wisconsin. The con-
clusion of a study commissioned by the Division of Public Health
found that targeted testing based on self-identified risk factors as
well as routinely available laboratory findings would require testing
less than 30% of inmates, but would capture almost 90% of those
with HCV infection. Risk factors for targeted screening include a his-
tory of IDU, liver disease, elevated ALT, HBV-positive, a history of
blood or blood product transfusion, hemodialysis, or organ/tissue
tr nsplantation.
Standard of Care
Dr. Jay Hoofnagle of the National Institute of Diabetes and Digestive
and Kidney Diseases reminded the participants that HCV - unlike
HIV - can be cured (with combination therapy). Based on available
evid nce, the best response to therapy occurs when patients are
treated early, are relatively young, have low levels of HCV RNA,
show less fibrosis on biopsy, and stop drinking before therapy.
Hoofnagle advised that the level of the HCV viral RNA alone does
not predict the response to therapy. Response to combination ther-
apy using pegylated interferon and ribivarin is generally 42% - 46%
for patients who have genotype 1 and 76% - 82% in patients who
have genotypes 2 and 3.
There was still some debate about what constitutes the "best" pos-
sible care (given the toxicity of treatment and the less-than-optimal
response rates in patients with genotype 1). However, for those indi-
v du s who meet treatment criteria, Hoofnagle stated that the stan-
dard of care is combination therapy with pegylated interferon and
ribivarin. Others pointed out that the number of inmates that can be
treated with combination therapy while incarcerated is a small per-
centage of the number testing positive for HCV - and that the real
"standard of care" is to make sure that all inmates are properly
scre ned, tested and counseled. Still others objected to establishing
a standard of care for HCV treatment in correctional settings without
s ff ient support in terms of resources and funding from the public
ealth sector.
Resources
The question of how to pay for hepatitis C testing, treatment, and
ducation (without sacrificing other essential health services) was
discussed at nearly every session. Of the few firm areas of consen-
sus reached, nearly everyone agreed that there isn't currently
enough money to screen, treat and educate inmates on HCV - and
there is no expectation that this will change anytime soon. Some
believe that lawsuits will force the issue - and others suggest that lit-
igation might be the only catalyst large enough to make a change in
legislative and public opinion. 
In the opinion of many attendees to the breakout session on
resources, the public health system, which has not yet begun to ade-
quately fill the need for HCV aftercare, needs to work with correc-
tion l health care professionals and legislatures to develop effective
ways to deal with HCV and other infectious diseases. Community
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Figure 1: Comparing HIV with Hepatitis C*
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*Chart adapted from Dr. Lemon's presentation by HEPP Report Staff.
Continued on page 7
7By Elizabeth Herbert*
Prevention and Control of Hepatitis Viruses in Corrections: CDC Guideline Summary
The CDC issued new recommendations
(available at http://www.cdc.gov/mmwr/pre-
view/ mmwrhtml/rr5201a1.htm) for control-
ling the spread of viral hepatitis in U.S. cor-
rectional facilities. The recommendations,
published in the January 24, 2003 "Morbidity
and Mortality Weekly Report," call for vacci-
nation against hepatitis B for all inmates and
vaccination against hepatitis A for at-risk
inmates. Previous recommendations had
called for vaccinating only long-term
inmates. The report also recommends test-
ing prisoners with a history of injection drug
use (IDU) for hepatitis C. 
The recommendations also provide guide-
lines for juvenile and adult correctional sys-
tems regarding identification and investiga-
tion of acute viral hepatitis; preexposure and
postexposure immunization for hepatitis A
and hepatitis B; hepatitis C screening, test-
ing and prevention; health education; and
release planning. 
Hepatitis A Virus (HAV) Vaccination
Incarcerated groups for whom hepatitis A
vaccination is recommended:
w Users of injection and noninjection illegal 
drugs
w Men who have sex with men
w Persons with chronic liver disease of any 
etiology (including HCV)
w Persons who receive blood product 
replacement therapy for clotting factor dis-
orders
The CDC recommends that for persons at
risk, the vaccination series should be initiat-
ed as soon as possible after incarceration.
Jails and prisons should implement tracking
systems if not already in place, and should
facilitate completion of the second vaccine
dose for inmates who are released before
the second dose is administered. 
Hepatitis B Virus (HBV) Vaccination
The CDC recommends that all adults who
receive a medical evaluation in a correction-
al facility - jail or prison - should be given the
hepatitis B vaccine (unless they have proof
of completion of the vaccine series or sero-
logic evidence of immunity). This includes
inmates entering correctional facilities as
well as those who are already incarcerated
and have not been previously vaccinated. 
For previously unvaccinated inmates with
less than a six-month term, the vaccine
series should be initiated and completed
using a four-month schedule (zero, one-two,
and four months). 
Although administration of the complete vac-
cine series should be the goal of all immu-
nization programs, the CDC notes that even
a single dose confers protective levels of
antibody, and the likelihood of completion of
the vaccination series should not be a factor
in offering it.
Hepatitis C Virus (HCV) Testing
The CDC recommends that all inmates be
asked questions about risk factors for HCV
infection upon intake, and that all inmates
reporting risk factors for HCV infection be
tested. Risk factors include testing inmates
who:
w Ever injected illegal drugs
w Received clotting factor concentrate 
produced before 1987
w Ever were on long-term hemodialysis
w Have evidence of chronic liver disease,
including persistently abnormal ALT levels
w Received a blood transfusion or an organ
transplant before July 1992.
The CDC also recommends that inmates
who test positive for HCV receive further
medical evaluation to determine evidence of
chronic infection and liver disease; be
immunized against HAV and HBV if not pre-
viously vaccinated; and be evaluated for
candidacy for antiviral therapy.
Elements of Hepatitis Health Education
The CDC recommends that health education
programs and curricula include:
w Routes of transmission
w Risk factors for infection
w Disease outcomes, the need for medical
management and treatment options
w Methods to prevent infection, including 
immunization and harm and risk reduction
counseling importance of not sharing drug
paraphernalia
w The importance of substance abuse treat-
ment, when appropriate
w Sexual precautions including abstinence
counseling and condom use
w Resources in the community available to
support and sustain a reduction in risk
behaviors.
Education can take different forms, including
videos, brochures, and formal classroom
presentations. However, repeated face-to-
face sessions have been determined to be
the most effective means of education. 
*Disclosures:Nothing to disclose.
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Hepatitis A vaccination dosages and schedule for adults                (Source: CDC, 2003)
Vaccine
Havrix 
VAQTA
Twinrix*
Dose
1,440 EL.U
50 U
720 EL.U
Volume(mL)
1.0
1.0
1.0
# of doses
2
2
3
Schedule(mos)
0 and 6-12
0 and 6
0,1, and 6
*Also contains hepatitis B vaccine antigen
*Both vaccines are routinely administered in a three-dose series, which includes schedules of zero,
one, and six months; zero, two, and four months; and zero, two, and six months. 
**Also contains hepatitis A vaccine antigen. 
***Special formulation
****Two 1.0mL doses administered at one site, in a four-dose schedule at zero, one-two, and six
months.
Hepatitis B vaccination dosages and schedule for adults                (Source: CDC, 2003)
Adults
Dialysis patients and
other immunocom-
promised persons
mg
10
40
mL
1.0
1.0***
mg
20
40
mL
1.0
2.0****
mg
20
-
mL
1.0
-
Recombivax HB* Engerix-B* Twinrix**
and community-based organizations (CBOs) need to play a role and
find ways to educate and treat in collaboration with corrections. With
some exceptions, CBOs have been silent on this issue, according to
health care professionals at the conference. 
A large barrier to effectively treating HCV after release from prison is
the lack of an equivalent to the Ryan White CARE Act. The very real
epidemic in the U.S. - not just in correctional facilities - needs atten-
tion from legislators (and the public) who can work to implement
funding and other components of support for managing HCV. Some
at the meeting suggest that correctional officials need to work with
their legislators and other elected officials to explain the needs and
issues facing corrections in order to allocate the necessary funds to
correctional health care budgets and ensure effective aftercare in
the community.
*Disclosures: Nothing to disclose.
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Management of HIV/AIDS in the
Correctional Setting Satellite
Videoconference
Hepatitis B & C with HIV 
Co-infection: A Diagnostic &
Treatment Update
March 11, 2003
12:30-3:30 p.m. Eastern Time
CME & Nursing Credits Available
Call: (518) 262-4674
E-mail: ybarraj@mail.amc.edu
Visit: www.amc.edu/Patient/HIV/
hivconf.htm
Improving the Management of
HIV Disease
March 28, 2003
New York, New York
Email: cme@iasusa.org
Visit: www.iasusa.org/cme/
15th National HIV/AIDS Update
Conference
Focusing on the Front Lines:
Practical Lessons in Prevention,
Treatment, and Care
March 30-April 2, 2003
Miami, Florida
Email: nauc@total.net
Visit: www.amfar.org/nauc
2003 ACHSA Multidisciplinary
Training Conference
Health Services and Security
Working Together in Harmony
Co-hosted by the CDC and HRSA
April 10-13, 2003
Baltimore, Maryland
Call: 877-918-1842
Email:  achsa@mindspring.com
Visit: www.corrections.com/achsa
Clinical Updates in Correctional
Health Care
NCCHC Spring Meeting
April 12-15, 2003
Anaheim, California
Call: 773.880.1460
Visit: www.ncchc.org
43rd Interscience Conference
on Antimicrobial Agents and
Chemotherapy (ICAAC)
September 14-17, 2003
Chicago, Illinois
Call: 202-737-3600
Email: icaac@asmusa.org
Visit: www.icaac.org/ICAAC.asp
The United States 
Conference on AIDS
Sponsored by the National
Minority AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
Save the 
Dates
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LA County Jails See Outbreak of Staph
Infections
An outbreak of drug-resistant Staphylococcus
aureus is spreading throughout the Los Angeles
County jail system, affecting more than 1,000
inmates in the last year and causing at least 57
hospitalizations. Federal officials say the out-
break is the largest of its kind in the nation's cor-
rectional systems. The infection, which causes
boils, deep skin abscesses and widespread sur-
rounding inflammation, was initially misdiag-
nosed as spider bites. Jail doctors are now
administering two antibiotics in tandem and
improving hygiene measures such as providing
inmates better access to showers and clean laun-
dry. Los Angeles Times, 1/31/03
HIV
Rapid HIV Test Extended to More Sites
U.S. Department of Health and Human Services
(HHS) has extended the availability of the
OraQuick Rapid HIV-1 Antibody Test from the
38,000 laboratories it was initially approved for to
more than 100,000 sites including jails, prisons,
physician offices, and HIV counseling centers.
The test, manufactured by Orasure Technologies
and marketed by Abbott Laboratories, uses a fin-
gerstick sample of blood and provides results
within 20 minutes. FDA Press Office, 1/31/03
Report: "Dangerous" Health Care at
Limestone
Prison Commissioner Donal Campbell released a
medical consultant¹s report that found "danger-
ous andextremely poor quality health care" at
Limestone Correctional Facility at Capshaw,
Alabama. The report, by Chicago-based
Jacqueline Moore and Associates, says the
death rate from AIDS at Limestone is more than
twice the national average in prisons, and that
efforts to control infectious and communicable
diseases at the facility were not adequately mon-
itored or reported. Medical services in Alabama
prisons are provided by NaphCare; NaphCare
officials state that some of the comments in the
report are "unsubstantiated and misleading."
Department of Corrections spokesman Brian cor-
bett said officials were asking NaphCare to follow
up on deficiencies based on the audits.
Associated Press, 2/13/03
HCV
Roche Reduces Cost of Copegus (ribavirin)
Roche has reduced the list price or wholesale
acquisition cost of Copegus (ribavirin) to $5.06
per 200 mg tablet. Roche's Pegasys (peginterfer-
on alfa-2a) and Copegus combination therapy
was approved by the FDA in December 2002.
PRNewswire, 1/13/03
Costs of Testing and Treating HCV in NJ
Published
Memos and emails obtained by the P iladelphia
Inquirerthrough the state's Open Records Act
indicate that the price of testing and treating
inmates in New Jersey prisons with the disease
could cost $4.5 to $8 million this year. The prison
medical provider, Correctional Medical Services
(CMS) projected that if just 25% of the state's
prison inmates were tested, it would cost $4.5
million a year for treatment and testing in accor-
dance with the Federal Bureau of Prisons guide-
lines, a standard New Jersey says it will meet. If
75% of the inmates were tested, annual costs
could reach $8.4 million, according to CMS docu-
ments. Philadelphia Inquirer, 1/12/03
ACLU Files Class-Action Lawsuit Against MI
Prisons
The American Civil Liberties Union (ACLU) filed a
class-action lawsuit in federal district court in
January, charging that Michigan prison officials
allowed HCV to reach epidemic proportions by
failing to adequately test and treat HCV+
inmates. The ACLU claims that state protocols for
testing and treatment fall short of accepted med-
ical standards, and that the state sometimes fails
to adhere to its own standards. The suit names
the Michigan Department of Corrections and
Correctional Medical Services as defendants. 
ACLU, 1/21/03
Inside News
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Resources & Websites
The Corrections Demonstration Project
www.sph.emory.edu/HIVCDP/Intro.htm
AIDS Education and Training Centers (AETC)
National Resource Center
www.aids-ed.org
CDC Division of HIV/AIDS Prevention
www.cdc.gov/hiv/pubs/guidelines.htm
CDC National Center for Infectious Diseases:
Hepatitis C
www.cdc.gov/ncidod/diseases/hepatitis/c/
STD/HIV Prevention Training Center (PTC)
www.stdhivpreventiontraining.org
The PTC is one of a group of federally funded
centers specializing in sexual and reproductive
health education for medical care providers. The
Seattle-based center offers education and skills
training in the diagnosis, treatment, and man-
agement of STDs.
NATAP HCV and HCV/HIV Handbook, 
Version 4
A 20-page handbook with simply written informa-
tion on treatment, prevention, transmission, epi-
demiology, and the latest study data on combi-
nation therapy of pegylated interferon plus rib-
avirin. Available in English and Spanish. For free
printed copies (including bulk copies) email
NATAP at tommy@natap.org. Available for
download at www.natap.org
Health Care and HIV: Nutritional Guide for
Providers and Clients, 2002
www.ask.hrsa.gov/detail.cfm?id=HAB00304
Published by the U.S. Department of Health and
Human Services. 
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through August 31, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The condition that occurs when viable M. tuberculosis organ-
isms remain dormant in the body is called:
(a) MDR TB
(b) Active TB
(c) LTBI
(d) None of the above
2. The safest and most effective treatment for drug-susceptible
LTBI is:
(a) Rifampin and pyrazinamide
(b) Rifampin
(c) Isoniazid
(d) Rifabutin
3. Treatment with the combination of rifampin and pyrazinamide
for LTBI is contraindicated in cases of:
(a) Pregnancy
(b) Those who have developed liver injury during prior 
treatment with isoniazid
(c) Patients who are receiving NNRTIs
(d) A and B
(e) All of the above
4. In patients who have symptoms consistent with TB disease, a
negative tuberculin skin test is useful in ruling out active TB. 
(a) True
(b) False
5. The strongest risk factor for progression from TB infection to
TB disease is:
(a) HIV infection
(b) Injection drug use 
(c) Cancer
(d) Diabetes
6. If there is suspicion that an individual has pulmonary TB dis-
ease, the first action should be to:
(a) Order a chest radiograph
(b) Collect sputum specimens
(c) Place the patient in a negative pressure respiratory 
isolation room
(d) Perform two-step skin testing 
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1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
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Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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